Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease Treated with Medications

Summary

This multi-center study will evaluate the safety and immune response to recombinant zoster vaccine (RZV) series in 264 patients with inflammatory bowel disease (IBD) on immunosuppressive therapy recruited from 6 study sites who can expect to be on study for up to 14 months.

Timeline

Start

2024-10

Primary completion

2027-09

Completion

2027-09

Outcome

Outcome not reported

Stopped (Business): “Funding ended”

Drugs

Indications